Champions Oncology, Inc.

NasdaqCM:CSBR Rapporto sulle azioni

Cap. di mercato: US$61.9m

Champions Oncology Gestione

Gestione criteri di controllo 4/4

Champions Oncology Il CEO è Ronnie Morris, nominato in Jan2017, e ha un mandato di 7.83 anni. la retribuzione annua totale è $ 400.00K, composta da 100% di stipendio e 0% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 6.32% delle azioni della società, per un valore di $ 3.91M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.8 anni e 13.4 anni.

Informazioni chiave

Ronnie Morris

Amministratore delegato

US$400.0k

Compenso totale

Percentuale dello stipendio del CEO100.0%
Mandato del CEO7.8yrs
Proprietà del CEO6.3%
Durata media del management3.8yrs
Durata media del Consiglio di amministrazione13.4yrs

Aggiornamenti recenti sulla gestione

Recent updates

Companies Like Champions Oncology (NASDAQ:CSBR) Can Afford To Invest In Growth

Oct 24
Companies Like Champions Oncology (NASDAQ:CSBR) Can Afford To Invest In Growth

It's A Story Of Risk Vs Reward With Champions Oncology, Inc. (NASDAQ:CSBR)

Jun 14
It's A Story Of Risk Vs Reward With Champions Oncology, Inc. (NASDAQ:CSBR)

Is Now The Time To Put Champions Oncology (NASDAQ:CSBR) On Your Watchlist?

Sep 28
Is Now The Time To Put Champions Oncology (NASDAQ:CSBR) On Your Watchlist?

Champions Oncology Non-GAAP EPS of -$0.02, revenue of $12.9M

Jul 21

We Think Some Shareholders May Hesitate To Increase Champions Oncology, Inc.'s (NASDAQ:CSBR) CEO Compensation

Oct 14
We Think Some Shareholders May Hesitate To Increase Champions Oncology, Inc.'s (NASDAQ:CSBR) CEO Compensation

We Think Champions Oncology (NASDAQ:CSBR) Can Afford To Drive Business Growth

Jun 21
We Think Champions Oncology (NASDAQ:CSBR) Can Afford To Drive Business Growth

Are Investors Undervaluing Champions Oncology, Inc. (NASDAQ:CSBR) By 44%?

Apr 09
Are Investors Undervaluing Champions Oncology, Inc. (NASDAQ:CSBR) By 44%?

Here's Why We're Not At All Concerned With Champions Oncology's (NASDAQ:CSBR) Cash Burn Situation

Mar 19
Here's Why We're Not At All Concerned With Champions Oncology's (NASDAQ:CSBR) Cash Burn Situation

The Champions Oncology (NASDAQ:CSBR) Share Price Has Gained 243%, So Why Not Pay It Some Attention?

Mar 02
The Champions Oncology (NASDAQ:CSBR) Share Price Has Gained 243%, So Why Not Pay It Some Attention?

Is There Now An Opportunity In Champions Oncology, Inc. (NASDAQ:CSBR)?

Feb 04
Is There Now An Opportunity In Champions Oncology, Inc. (NASDAQ:CSBR)?

Do Insiders Own Lots Of Shares In Champions Oncology, Inc. (NASDAQ:CSBR)?

Jan 14
Do Insiders Own Lots Of Shares In Champions Oncology, Inc. (NASDAQ:CSBR)?

Philip Breitfeld Is The Chief Strategy & Innovation Officer and Director of Champions Oncology, Inc. (NASDAQ:CSBR) And They Just Sold 100% Of Their Shares

Dec 19
Philip Breitfeld Is The Chief Strategy & Innovation Officer and Director of Champions Oncology, Inc. (NASDAQ:CSBR) And They Just Sold 100% Of Their Shares

Champions Oncology, Inc. (NASDAQ:CSBR) Analysts Are Pretty Bullish On The Stock After Recent Results

Dec 16
Champions Oncology, Inc. (NASDAQ:CSBR) Analysts Are Pretty Bullish On The Stock After Recent Results

Champions Oncology beats on revenue

Dec 14

Estimating The Fair Value Of Champions Oncology, Inc. (NASDAQ:CSBR)

Dec 04
Estimating The Fair Value Of Champions Oncology, Inc. (NASDAQ:CSBR)

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Ronnie Morris rispetto agli utili di Champions Oncology?
DataCompenso totaleStipendioGuadagni aziendali
Jul 31 2024n/an/a

-US$3m

Apr 30 2024US$400kUS$400k

-US$7m

Jan 31 2024n/an/a

-US$10m

Oct 31 2023n/an/a

-US$10m

Jul 31 2023n/an/a

-US$8m

Apr 30 2023US$600kUS$400k

-US$5m

Jan 31 2023n/an/a

-US$3m

Oct 31 2022n/an/a

US$108k

Jul 31 2022n/an/a

US$401k

Apr 30 2022US$800kUS$400k

US$548k

Jan 31 2022n/an/a

US$219k

Oct 31 2021n/an/a

US$391k

Jul 31 2021n/an/a

US$115k

Apr 30 2021US$775kUS$375k

US$362k

Jan 31 2021n/an/a

-US$1m

Oct 31 2020n/an/a

-US$2m

Jul 31 2020n/an/a

-US$1m

Apr 30 2020US$1mUS$394k

-US$2m

Jan 31 2020n/an/a

-US$181k

Oct 31 2019n/an/a

-US$956k

Jul 31 2019n/an/a

-US$995k

Apr 30 2019US$146kUS$146k

US$128k

Jan 31 2019n/an/a

-US$251k

Oct 31 2018n/an/a

US$42k

Jul 31 2018n/an/a

-US$320k

Apr 30 2018US$244kn/a

-US$1m

Compensazione vs Mercato: La retribuzione totale di Ronnie ($USD 400.00K ) è inferiore alla media delle aziende di dimensioni simili nel mercato US ($USD 649.07K ).

Compensazione vs guadagni: La retribuzione di Ronnie è stata coerente con le performance aziendali dell'ultimo anno.


AMMINISTRATORE DELEGATO

Ronnie Morris (58 yo)

7.8yrs

Mandato

US$400,000

Compensazione

Dr. Ronnie Morris, M.D. has been Chief Executive Officer at Champions Oncology, Inc. since January 31, 2017. Dr. Morris previously served as the President and a Director of Champions Oncology, Inc. from Oc...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Ronnie Morris
CEO & Director7.8yrsUS$400.00k6.32%
$ 3.9m
David Miller
Chief Financial Officer7.5yrsUS$260.00k0.041%
$ 25.1k
Maria Mancini
Chief Operating Officer1.3yrsNessun datoNessun dato
Arthur Hanson
Vice President of Technology4.5yrsNessun datoNessun dato
Rachel Bunting
Vice President of Global Marketingno dataNessun datoNessun dato
Michael Ritchie
Chief Commercial Officerno dataNessun datoNessun dato
Karin Heidemann
Executive Vice President of Global Scientific Operations3.2yrsNessun datoNessun dato
Marianna Zipeto
Executive Vice President of Commercial1.3yrsNessun datoNessun dato

3.8yrs

Durata media

Gestione esperta: Il team dirigenziale di CSBR è considerato esperto (durata media dell'incarico 3.8 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Ronnie Morris
CEO & Director14.1yrsUS$400.00k6.32%
$ 3.9m
Scott Tobin
Independent Director13.4yrsUS$93.30k0.22%
$ 136.5k
Joel Ackerman
Independent Chairman of the Board14.1yrsUS$116.62k7.08%
$ 4.4m
David Sidransky
Independent Lead Director17.3yrsUS$85.54k5.64%
$ 3.5m
René Bernards
Scientific Advisorno dataNessun datoNessun dato
Manuel Hidalgo
Scientific Advisorno dataNessun datoNessun dato
Daniel Mendelson
Independent Director11.7yrsUS$85.52k1.46%
$ 903.7k
Harvey Pass
Scientific Advisorno dataNessun datoNessun dato
Philip Breitfeld
Independent Director8.6yrsUS$85.54k0.11%
$ 66.6k
Misti Ushio
Board Observerno dataNessun datoNessun dato
Justin Stebbing
Scientific Advisorno dataNessun datoNessun dato
Robert Brainin
Independent Director3.8yrsUS$82.20k0%
$ 0

13.4yrs

Durata media

58.5yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di CSBR è composto da personale esperto e esperto (durata media dell'incarico 13.4 anni).